Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 3, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children age 2 years through 18 years
jRCT2080223345Phase 3
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing MEDI3250 with Placebo (2 arms). Primary endpoint: Incidence of symptomatic influenza due to any wild-type influenza virus.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2080223345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223345.